This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Visalli, M. A.
Right arrow Articles by Appelbaum, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Visalli, M. A.
Right arrow Articles by Appelbaum, P. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1998, p. 2002-2005, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Activities of Three Quinolones, Alone and in Combination with Extended-Spectrum Cephalosporins or Gentamicin, against Stenotrophomonas maltophilia

Melissa A. Visalli,1 Michael R. Jacobs,2 and Peter C. Appelbaum1,*

Department of Pathology (Clinical Microbiology), Hershey Medical Center, Hershey, Pennsylvania 17033,1 and Department of Pathology, Case Western Reserve University, Cleveland, Ohio 441062

Received 24 March 1998/Returned for modification 6 May 1998/Accepted 28 May 1998

The present study examined the activities of trovafloxacin, levofloxacin, and ciprofloxacin, alone and in combination with cefoperazone, ceftazidime, cefpirome, and gentamicin, against 100 strains of Stenotrophomonas maltophilia by the MIC determination method and by synergy testing of the combinations by the time-kill and checkerboard titration methods for 20 strains. The respective MICs at which 50% and 90% of isolates were inhibited for the drugs used alone were as follows: trovafloxacin, 0.5 and 2.0 µg/ml; levofloxacin, 2.0 and 4.0 µg/ml; ciprofloxacin, 4.0 and 16.0 µg/ml; cefoperazone, >128.0 and >128.0 µg/ml; ceftazidime, 32.0 and >128.0 µg/ml; cefpirome, >128.0 and >128.0 µg/ml; and gentamicin, 128.0 and >128.0 µg/ml. Synergistic fractional inhibitory concentration indices (<= 0.5) were found for >= 50% of strains for trovafloxacin-cefoperazone, trovafloxacin-ceftazidime, levofloxacin-cefoperazone, levofloxacin-ceftazidime, ciprofloxacin-cefoperazone, and ciprofloxacin-ceftazidime, with other combinations affecting fewer strains. For 20 strains tested by the checkerboard titration and time-kill methods, synergy (>= 100-fold drop in count compared to the count achieved with the more active compound) was more pronounced after 12 h due to regrowth after 24 h. At 12 h, trovafloxacin at 0.004 to 0.5 µg/ml showed synergy with cefoperazone for 90% of strains, with ceftazidime for 95% of strains with cefpirome for 95% of strains, and with gentamicin for 65% of strains. Levofloxacin at 0.03 to 0.5 µg/ml and ciprofloxacin at 0.5 to 2.0 µg/ml showed synergy with cefoperazone for 80% of strains, with ceftazidime for 90 and 85% of strains, respectively, with cefpirome for 85 and 75% of strains, respectively, and with gentamicin for 65 and 75% of strains, respectively. Time-kill assays were more discriminatory than checkerboard titration assays in demonstrating synergy for all combinations.

* Corresponding author. Mailing address: Department of Pathology, Hershey Medical Center, P.O. Box 850, Hershey, PA 17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail: pappelbaum{at}psghs.edu.

Antimicrobial Agents and Chemotherapy, August 1998, p. 2002-2005, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Pankuch, G. A., Lin, G., Seifert, H., Appelbaum, P. C. (2008). Activity of Meropenem with and without Ciprofloxacin and Colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob. Agents Chemother. 52: 333-336 [Abstract] [Full Text]  
  • Gesu, G. P., Marchetti, F., Piccoli, L., Cavallero, A. (2003). Levofloxacin and Ciprofloxacin In Vitro Activities against 4,003 Clinical Bacterial Isolates Collected in 24 Italian Laboratories. Antimicrob. Agents Chemother. 47: 816-819 [Abstract] [Full Text]  
  • Gradelski, E., Valera, L., Bonner, D., Fung-Tomc, J. (2001). Synergistic Activities of Gatifloxacin in Combination with Other Antimicrobial Agents against Pseudomonas aeruginosa and Related Species. Antimicrob. Agents Chemother. 45: 3220-3222 [Abstract] [Full Text]  
  • Ednie, L. M., Credito, K. L., Khantipong, M., Jacobs, M. R., Appelbaum, P. C. (2000). Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods. J Antimicrob Chemother 45: 633-638 [Abstract] [Full Text]  
  • Weiss, K., Restieri, C., De Carolis, E., Laverdiere, M., Guay, H. (2000). Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 45: 363-365 [Abstract] [Full Text]  
  • Clark, C. L., Jacobs, M. R., Appelbaum, P. C. (1999). Activities of Clinafloxacin, Alone and in Combination with Other Compounds, against 45 Gram-Positive and -Negative Organisms for Which Clinafloxacin MICs Are High. Antimicrob. Agents Chemother. 43: 2295-2298 [Abstract] [Full Text]  
  • Bonacorsi, S., Fitoussi, F., Lhopital, S., Bingen, E. (1999). Comparative In Vitro Activities of Meropenem, Imipenem, Temocillin, Piperacillin, and Ceftazidime in Combination with Tobramycin, Rifampin, or Ciprofloxacin against Burkholderia cepacia Isolates from Patients with Cystic Fibrosis. Antimicrob. Agents Chemother. 43: 213-217 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»